Abstract

BackgroundTo evaluate the impact of age-related macular degeneration (AMD) on the quality of life (QoL) in a Brazilian population using The National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25).MethodsThis observational study included 462 participants from the Departments of Ophthalmology of the University of Campinas and Conderg-Divinolândia. The NEI-VFQ-25 questionnaire and Rasch analysis were used to assess the vision-related quality of life (VRQoL). Patients with macular neovascularization were interviewed at enrollment and after three loading doses of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.ResultsOne hundred thirty-three patients were excluded because they had another ophthalmic disease, for a total of 349 patients included in the study (177 in the AMD group, 172 in the control group; 56.4% were women; mean ± standard deviation age, 70.6 ± 9.5 years). Most NEI-VFQ-25 subscale scores were significantly lower in the AMD group compared with the control group. The Rasch-calibrated NEI-VFQ-25 median score in the visual-functioning component was 56.41 for the AMD group and 61.53 for the control group, a difference of ± 4.00 (P = 0.0001). Separate analyses of the sociodemographic and ocular characteristics showed that the NEI-VFQ-25 scores were affected mostly by family income, educational level, descent, diet (vegetables/fruits), physical activity, and visual acuity (VA). The longitudinal component assessed a different group of 48 patients with exudative disease treated with anti-VEGF drugs. The mean logarithm of the minimum angle of resolution change in VA in treated eyes was a 0.16 decrease (P = 0.01). The mean change in the optical coherence tomography macular thickness was a 36.74-μm decrease (P = 0.012) from baseline to 4 months. The mean NEI-VFQ-25 scores improved significantly from baseline to follow-up at 4 months in almost all subscales.ConclusionsIn a Brazilian community, patients with AMD had a worse VRQoL than controls. The AMD severity and bilaterality were associated with decreased NEI-VFQ-25 scores. Higher family income, educational level, descent, and lifestyle significantly improved several subscales of the NEI-VFQ-25 questionnaire. Treated patients with exudative AMD had improvements in the VA, macular thickness, and most NEI-VFQ-25 subscale scores.

Highlights

  • To evaluate the impact of age-related macular degeneration (AMD) on the quality of life (QoL) in a Brazilian population using The National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)

  • Because previous analyses have shown that QoL is more correlated with visual acuity (VA) in the eye with better version [16, 17], the patients were divided into three subgroups to assess their QoL: subgroup 1 included patients with at least one eye at stage 2 or 3, subgroup 2 included those with one eye at stage 2 or 3 and the other eye at stage 4 or 5, and subgroup 3 included those with both eyes at stage 4 or 5

  • We evaluated how AMD affected VA and health-related QoL (HRQoL) using the traditional NEI-VFQ-25 analysis and results calibrated with a separate Rasch analysis; the Rasch analysis separated the socioemotional component from the visual function component

Read more

Summary

Introduction

To evaluate the impact of age-related macular degeneration (AMD) on the quality of life (QoL) in a Brazilian population using The National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25). Age-related macular degeneration (AMD) is a chronic progressive disease that mainly affects the central retina. Roque et al Int J Retin Vitr (2021) 7:20 reach 288 million in 2040 [1]. These numbers make AMD one of the leading causes of blindness in adults over 50 years of age, according to the World Health Organization [1]. In 2019, Spaide et al purposed a consensus classification of neovascular AMD based mainly on optical coherence tomography (OCT) and OCT angiography findings and classified wet AMD into macular neovascularization types I, II, and III, and dry AMD into the outer retinal atrophy and the retinal pigment epithelial atrophy

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call